Stay updated on KD025 Efficacy and Safety in cGVHD Clinical Trial
Sign up to get notified when there's something new on the KD025 Efficacy and Safety in cGVHD Clinical Trial page.

Latest updates to the KD025 Efficacy and Safety in cGVHD Clinical Trial page
- Check2 days agoChange DetectedThe ClinicalTrials.gov page displays the ROCKstar Phase 2 belumosudil study record, including its terminated status, results, eligibility criteria, study locations, and supporting documents.SummaryDifference73%

- Check9 days agoChange DetectedThe ClinicalTrials.gov page remains a 403 Forbidden error rather than showing the study record. The footer revision identifier changes from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check16 days agoChange DetectedA site-wide NIH banner announces a transition in terminology, saying federal agencies are using “Super Intelligence” in place of “Artificial Intelligence.” The clinical study record remains inaccessible behind a 403 error.SummaryDifference1%

- Check23 days agoChange DetectedThe footer revision label was updated from v3.7.1 to v3.7.2, while the page remains a 403 Forbidden error.SummaryDifference0.2%

- Check30 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check51 days agoChange DetectedThe study record page now displays a 403 Forbidden error, replacing the usual content and blocking access to the study details.SummaryDifference19%

Stay in the know with updates to KD025 Efficacy and Safety in cGVHD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KD025 Efficacy and Safety in cGVHD Clinical Trial page.